Author Bio
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies. Follow @BudwellGeorge
What happened
Shares of
Biohaven Pharmaceutical Holding Co. (NYSE:BHVN) dropped by nearly 13% in pre-market action Tuesday morning. The drugmaker s shares are sinking following the release of disappointing phase 2/3 clinical trial results for its experimental Alzheimer s disease drug known as troriluzole.
Specifically, the company announced yesterday that troriluzole failed to beat out placebo at the 48-week mark in patients with mild to moderate Alzheimer s disease on two measures of cognitive decline: the Alzheimer s Disease Assessment Scale-Cognitive Subscale 11 and the Clinical Dementia Rating Scale Sum of Boxes.
/PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary.
Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease in Positive Phase 2 Trial
Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease
in Positive Phase 2 Trial
BASINGSTOKE, January 12, 2021 – Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer’s disease compared to placebo in results from Eli Lilly and Company’s Phase 2 TRAILBLAZER-ALZ study. Donanemab met the primary endpoint of change from baseline to 76 weeks in the Integrated Alzheimer s Disease Rating Scale (iADRS), slowing decline by 32 percent relative to placebo, which was statistically significant. The iADRS is a clinical composite tool combining the cognitive measure ADAS-Cog13 and functional measure ADCS-iADL, two commonly used measures in Alzheimer’s disease. Donanemab also
/PRNewswire/ Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a.
Share:
PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER S DISEASE MET ITS PRIMARY ENDPOINT
MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL
AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS
Paris, December 16, 2020, 8am CET
AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer s disease met its predefined primary endpoint.
Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase